The European Commission will authorise a new contract for the future supply of a covid-19 vaccine, Commission President Ursula von der Leyen said on Wednesday.
This contract, with German company CureVac, will be the Commission's fifth advance purchase contract with a pharmaceutical company.
The contract will cover the possible supply of up to 405 million doses, von der Leyen announced.
We continue to work to secure safe & effective vaccines to end the pandemic.I am glad to announce a new agreement to buy up to 405 million doses of a vaccine produced by the European company @CureVacRNAhttps://t.co/H1gFQH7FAX — Ursula von der Leyen (@vonderleyen) November 16, 2020
Since the Commission presented its strategy of centralised negotiations on behalf of the Member States, it has aimed to build up a portfolio of different vaccines. The Commission has already signed advance purchase agreements already concluded with Pfizer-BioNTech, AstraZeneca, Belgium's Janssen (Johnson & Johnson), and Sanofi-GSK.
They are all still at the trial stage, and none of them are currently authorised on the European market.
This will only happen if a vaccine successfully completes the whole testing process and is deemed sufficiently effective and safe to be authorised for marketing in the EU.
- Latest Covid-19 vaccine is over 90% effective, creator says
- Coronavirus vaccine will ‘not replace’ other tools, WHO warns
This will ultimately require a green light from the European Medicines Agency (EMA). However, its evaluation and authorisation procedure are being sped up through a "rolling review", meaning that information from the trials is passed on throughout the procedure rather than in a single dossier at the end of the process.
The Commission is also in advanced discussions with the American company Moderna, who earlier today announced that its vaccine was 94.5% effective.
The Brussels Times